UK's AMRC Licenses Shionogi Superbug Therapy
As it waits for a US FDA decision on its antibiotic cefiderocol, the Japanese company has handed over the rights to a Pseudomonas aeruginosa therapy that will go into the clinic next year.
You may also be interested in...
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
The Swiss group's one-dose drug, seen as a future growth driver, is as effective as its off-patent blockbuster Tamiflu in treating children.
Shionogi’s novel single-dose flu drug shows promise in first Phase III results in post-exposure prevention, paving the way for a Japanese filing in this setting and potentially expanding already healthy sales.